Proposal for translational analysis and development of clinical radiolabeled immunoglobulin therapy

Radiotherapy and Oncology

Volumn 41, Issue 2, 1996, Pages 151-161

  Vriesendorp, Huibert M ^a   Quadri, Syed M ^a   Jaeckle, Kurt A ^a   Freedman, Ralph S ^a   Cromeens, D M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

human immunoconjugates; indium 111; RIT development; translational analysis; yttrium 90

Indexed keywords

ANTIBODY CONJUGATE; IMMUNOGLOBULIN; INDIUM 111; MONOCLONAL ANTIBODY; PENTETIC ACID; POLYCLONAL ANTIBODY; YTTRIUM 90;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; HODGKIN DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MONKEY; MOUSE; NUDE MOUSE; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; TUMOR XENOGRAFT;

ANIMALS; CLINICAL PROTOCOLS; DOGS; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; MACACA MULATTA; MICE; MICE, NUDE; RABBITS; RADIOIMMUNOTHERAPY; YTTRIUM RADIOISOTOPES;

EID: 0030294482     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(96)01829-4     Document Type: Article

References (43)

1. [1] Bierman, P.J., Vose, J.M., Leichner, P.K., Quadri, S.M., Armitage, J.O., Klein, J.L., Abrams, R.A., Dicke, K.A. and Vriesendorp, H.M. Yttrium-90-labeled antiferritin followed by high-dose chemotherapy and autologous bone marrow transplantation for poor prognosis Hodgkin's disease. J. Clin. Oncol. 11: 698-703, 1993.
2. [2] Buchsbaum, D.J., Khazaeli, M.B., Bright, S.J. and Meredith, R.F. Fractionated radioimmunotherapy of human colon carcinoma xenografts with 131-I-CC49 monoclonal antibody. J. Immunother. 16: 156, 1994.
3. [3] Chen, P.P., Freedman, R.S., Chernajarsky, Y. and Platsoucas, C.D. Amplification of immunoglobulin transcripts by the non-palindromic adoption polymerase chain reactive (NPA-PCR) nucleotide sequence analysis of two human monoclonal antibodies recognizing two cell surface antigens expressed in ovarian, cervix, breast, colon, and other carcinomas. Hum. Antibodies Hybridomas 5: 131-143, 1994.
4. [4] Epenetos, A.A., Murro, A.J., Stewart, S. et al. Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies. J. Clin. Oncol. 5: 1890-1899, 1987.
5. [5] Fowler, J.F. Radiobiological aspects of low dose rates in immunotherapy. Int. J. Radiat. Oncol. Biol. Phys. 18: 1261-1269, 1990.
6. [6] Freedman, R.S., Ioannides, L.G., Tomasonic, B., Patenia, R., Zhang, H.Z., Liang, T. and Edwards, C.L. Development of a cell surface-reacting human monoclonal antibody agent in ovarian carcinoma. Hybridoma 10: 21-33, 1991.
7. [7] Goldenberg, D.M. Future role of monoclonal antibodies in oncological diagnosis and therapy. Semin. Nucl. Med. 19: 332-345, 1989.
8. [8] Grossbard, M.L., Press, O.P., Appelbaum, F.R., Bernstein, I.D. and Nadler, L.M. Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 80: 863-878, 1992.
9. [9] Herbst, J.M., Klein, J.L., Leichner, P.K., Quadri, S.M. and Vriesendorp, H.M. Survival of patients with resistant Hodgkin's disease after polyclonal yttrium-90-labeled antiferritin treatment. J. Clin. Oncol. 13: 2394-2400, 1995.
10. [10] Ingold, J.H., Reed, G.B., Kaplan, H.S. and Bayshaw, M.A. Radiation hepatitis, Am. J. Radiol. 93: 200-206, 1965.
11. [11] Jaeckle, K.A. Paraneoplastic neurological diseases in cancer of the nervous system. Editor: V. Levin. Churchill Livingstone, New York (in press).
12. 2 fragment of an anti CEA monoclonal antibody. Radiology 174: 147-151, 1990.
13. [13] Larson, S.M. Lymphoma, melanoma, colon cancer diagnosis and treatment with radiolabeled monoclonal antibodies. Radiology 165: 297-304, 1987.
14. [14] Leichner, P.K. and Kwok, C.S. Tumor dosimetry in radioimmunotherapy: methods of calculation for beta particles. Med. Phys. 29: 529-534, 1993.
15. [15] Leichner, P.K., Koral, K.F., Jaszczak, R.J., Green, A.J., Chen, G.T.Y. and Roeske, J.C. An overview of imaging techniques and physical aspects of treatment planning in radioimmunotherapy. Med. Phys. 20: 569-577, 1993.
16. [16] Lenhard, R.E., Order, S.E., Spunberg, J.J., Asbell, S.O. and Leibel, S.A. Isotopic immunoglobulin: a new systemic therapy for advanced Hodgkin's disease. J. Clin. Oncol. 3: 1296-1300, 1985.
17. [17] Markoe, A.M., Brady, W., Woo, D. et al. Treatment of gastrointestinal cancer using monoclonal antibodies. Front. Radiat. Ther. Oncol. 24: 214-224, 1990.
18. [18] Molthoff, C.F.M., Pinedo, H.M., Schlüper, H.M.M. and Boven, E. Influence of dose and schedule on the therapeutic efficacy of 131-I-labeled monoclonal antibody 139H2 in a human ovarian cancer xenograft model. Int. J. Cancer 50: 474-480, 1992.
19. [19] Murray, J.L., Macey, D.J., Kasi, L.P., Rieger, P. et al. Phase II radioimmunotherapy trial with 131-I-CC49 in colorectal cancer. Cancer 73: 1057-1066, 1994.
20. [20] Olive, D. and Mawas, C. Therapeutic applications of anti-CD4 antibodies. Crit. Rev. Ther. Drug Carrier Syst. 10: 29-63, 1993.
21. [21] Press, D.W., Eary, J.F. and Badger, C.C. High dose radioimmunotherapy of B cell lymphoma. Front. Radiat. Ther. Oncol. 24: 104-113, 1990.
22. [22] Quadri, S.M., Vriesendorp, H.M., Leichner, P.R. and Williams, J.R. Evaluation of indium-111 and yttrium-90 labeled linker-immunoconjugates in nude mice and dogs. J. Nucl. Med. 34: 938-945, 1993.
23. [23] Quadri, S.M. and Mohammedpour, H. A convenient synthesis of 2-p-aminobenzyl-3-methyl and 2-p-aminobenzyl-3-benzyl derivatives of diethylenetriaminepentaacetic acid (DTPA): carbon backbone-modified bifunctional chelating agents. Bioorg. Med. Chem. Lett. 2, 1661-1664, 1992.
24. 2 fragments of monoclonal antiferritin antibody in a nude mouse model. J. Nucl. Med. 34: 2152-2159, 1993.
25. [25] Quadri, S.M., Siddigui, A., Klein, J.L. and Vriesendorp, H.M. Biodistribution and tumor localization of indium-111-labeled unmodified and modified F(ab′)2 fragments of human monoclonal IgM (16.88) in a nude mouse model. Nucl. Med. Biol. 22: 413-423, 1995.
26. [26] Quadri, S.M., Shao, Y., Blum, J.E., Leichner, P.K., Williams, J.R. and Vriesendorp, H.M. Preclinical evaluation of intravenously administered indium-111 and yttrium-90 labeled B72.3 immunoconjugate (GYK-DTPA) in beagle dogs. Nucl. Med. Biol. 10: 559-570, 1993.
27. [27] Quadri, S.M., Malik, A.B., Tang, X.Z., Patenia, R., Freedman, R.S. and Vriesendorp, H.M. Preclinical analysis of intraperitoneal administration of indium-111-labeled human monoclonal IgM (AC6C3). Cancer Res. 55: 5736s-5742s, 1995.
28. [28] Riva, R., Arista, A., Tison, V., Sturiale, C. et al. Intralesional radioimmunotherapy of malignant gliomas: an effective treatment in recurrent tumors. Cancer 73: 1076-1082, 1994.
29. [29] Scheinberg, D.A., Lovett, D., Divgi, C.R., Graham, M.C., Berman, E., Pentlow, K., Feist, N., Finn, R.D., Clarkson, B.D., Gee, T.S., Larson, S.M., Oettgewn, H. and Old, L.J. A Phase I trial of monoclonal antibody M195 in acute myelogeneous leukemia: specific bone marrow targeting and internalization of radionuclides. J. Clin. Oncol. 24: 194-201, 1991.
30. [30] Schlom, J. Monoclonal antibodies. They are more and less than you think. In: Molecular Foundations of Oncology, pp. 95-134. Editor: S. Broder. Williams & Wilkins, Baltimore, 1991.
31. [31] Schlom, J., Molinolio, H., Simpson, J.F., Siler, K., Roselli, M., Hinkle, G., Houchens, D.P. and Colcher, D. Advantage of dose fractionation in monoclonal antibody targeted radioimmunotherapy. J. Natl. Cancer Inst. 82: 763-771, 1990.
32. [32] Stewart, F.A. Radiation nephropathy after abdominal irradiation or total body irradiation. Radiat. Res. 143, 235-237, 1995.
33. [33] Vaughan, A.T.M., Bradwell, A.R., Dykes, P.W. and Anderson, P. Illusions of tumor killing using radiolabeled antibodies. Lancet 1: 1492-1493, 1986.
34. [34] Vriesendorp, H.M., Quadri, S.M., Stinson, R.L., Onyekwere, O.G., Shao, Y., Klein, J.L., Leichner, P.K. and Williams, J.R. Selection of reagents for human radioimmunotherapy. Int. J. Radiat. Oncol. Biol. Phys. 22: 37-45, 1992.
35. [35] Vriesendorp, H.M., Morton, J.D. and Quadri, S.M. A review of five consecutive studies of radiolabeled immunoglobulin therapy in patients with endstage Hodgkin's disease. Cancer Res. 55: 5888s-5892s, 1995.
36. [36] Vriesendorp, H.M., Quadri, S.M. and Williams, J.R. Radioimmunoglobulin therapy. In: High Dose Cancer Therapy. Pharmacology, Hematopoietins, Stem Cells, Chapter 5, pp. 84-123. Editors: J.O. Armitage and K.H. Antman. Williams & Williams, Baltimore, 1992.
37. [37] Vriesendorp, H.M., Shao, I., Blum, J.E., Quadri, S.M. and Williams, J.R. Fractionated intravenous administration of site-specific yttrium-90 labeled B72.3 GYK DTPA immunoconjugate in beagle dogs. Nucl. Med. Biol. 20: 571-578, 1993.
38. [38] Vriesendorp, H.M., Herpst, J.M., Germack, M.A., Klein, J.L., Leichner, P.K., Loudenslager, D.M. and Order, S.E. Phase I-II studies of yttrium-labeled antiferritin for end-stage Hodgkin's disease including RTOG 87-01. J. Clin. Oncol. 9: 918-928, 1991.
39. [39] Vriesendorp, H.M. Similarities between HL-A and major histocompatibility complexes of subhuman primates. In: Progressi nei Trapiante d'Organo e Negli Organi Artificiali, p. 539. Editors: C. Scotti Foglieni, G. Pedroni, G.S. Donati, R. Cortesini and R. Cortinovis. La Typografica Varese, 1976.
40. [40] Vriesendorp, H.M., Dicke, K.A. and Quadri, S.M. Radioimmunotherapy for bone marrow transplantation patients. In: Proceedings of the 6th International Symposium on Autologus Bone Marrow Transplantation, pp. 98-101. Editors: K.A. Dicke and A. Keating. Cancer Treatment Research Education Fund, Arlington, Texas, 1993.
41. [41] Waldman, H. Manipulation of T-cell responses with monoclonal antibodies. Annu. Rev. Immunol. 7: 407-444, 1989.
42. [42] Wang, S., Quadri, S.M., Tang, X.Z., Stephens, L.C., Lollo, C.P., Bartholomew, R.M. and Vriesendorp, H.M. Liver toxicity induced by combined external beam irradiation and radioimmunoglobulin therapy. Radiat. Res. 141: 294-302, 1995.
43. [43] Wilbur, O.S. Potential use of alpha emitting radionuclides in the treatment of cancer. Antibody Immunoconjug. Radiopharm. 4: 85-97, 1991.